Skip to main navigation

Beam - Top Menu

About Us
Our Science
Our Portfolio
Investor Center
Careers
Contact

Investor Center

Investors & Media

Overview
Press Releases
Events
Scientific Posters & Presentations
Publications
Financials & Filings
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
Analyst Coverage
Corporate Governance
Investor FAQs
Contact Us

Stockholder Tools

Print Page
RSS Feeds
Share Page
Email Alerts

Press Releases

Year

January 9, 2022

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Type Ia Nomination of Two Additional Development Candidates

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 12 of 12

Investors & Media

Overview
Press Releases
Events
Scientific Posters & Presentations
Publications
Financials & Filings
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
Analyst Coverage
Corporate Governance
Investor FAQs
Contact Us

Stockholder Tools

Print Page
RSS Feeds
Share Page
Email Alerts

Beam - Top Menu

About Us
Our Science
Our Portfolio
Investor Center
Careers
Contact

Privacy Policy

Facebook
Twitter
LinkedIn